Evidence map›Paper›PMID 39519010›Full record

ArticleInternational journal of molecular sciences2024

Jakob K Reinhardt, Lukas Schertler, Hendrik Bussmann, Manuel Sellner, Martin Smiesko, Georg Boonen, Olivier Potterat, Matthias Hamburger, Veronika Butterweck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Clinical evaluation of the efficacy ofFrontiers in veterinary science · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jakob K ReinhardtDepartment of Pharmaceutical Sciences, Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
Lukas SchertlerMedical Department, Max Zeller Soehne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Hendrik BussmannMedical Department, Max Zeller Soehne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Manuel SellnerDepartment of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.ORCID 0000-0003-3961-0175
Martin SmieskoDepartment of Pharmaceutical Sciences, Computational Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.ORCID 0000-0003-2758-2680
Georg BoonenMedical Department, Max Zeller Soehne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Olivier PotteratDepartment of Pharmaceutical Sciences, Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.ORCID 0000-0001-5962-6516
Matthias HamburgerDepartment of Pharmaceutical Sciences, Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.ORCID 0000-0001-9331-273X
Veronika ButterweckMedical Department, Max Zeller Soehne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.ORCID 0000-0001-7516-8789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-clinical studies suggest that extracts prepared from the fruits of

Indexed as

CricetulusDiterpenesMolecular Docking SimulationPlant ExtractsReceptors, Dopamine D2TriterpenesVitexAnimalsCHO CellsHumansDiterpenesPlant ExtractsReceptors, Dopamine D2TriterpenesD2 receptorditerpenemicrofractionationmolecular dockingtriterpeneVitex agnus castus

Identifiers

PMID39519010
PMCPMC11547015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.